NeuroSolutions Ltd was incorporated on 12 April 2001 having originated from the University of Warwick in the United Kingdom. NeuroSolutions is a neurology research and development company, with a current focus on the treatment of pain. Its most advanced programme is for the treatment of pain, in particular lead compound NSL-043 is currently in clinical development, which is being jointly funded with a clinical partner from Japan, Sosei Co Ltd.

Company was acquired by NeuroDiscovery Ltd.